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ABSTRACT
Introduction: Recombinant human growth 
hormone (rhGH) is effective and safe when used 
to treat growth hormone deficiency (GHD) in 
children. However, it has been suggested that 
switching between different types of rhGH can 
have a detrimental effect on patients. Methods:
The current analysis assessed the efficacy 
and safety of rhGH in children who received 
continuous Omnitrope® (Sandoz GmbH, Kundl, 
Austria) therapy either with lyophilized powder 
for solution or ready-to-use solution, with 
children who received 9 months of treatment 
with Genotropin® (Pfizer Limited, Sandwich, 
UK) followed by Omnitrope solution thereafter. 
Changes to height, height SD score (SDS), height 
velocity SDS, insulin-like growth factor (IGF-
1) levels, and IGF binding protein (IGFBP-3) 
levels were assessed using data from three trials. 
Results: Baseline demographics of the three 
study groups were similar. Over an 18-month 
period there were no observable differences 
between the three groups with respect to height, 
height SDS, height velocity SDS, IGF-1 levels, 
and IGFBP-3 levels. This result was corroborated 
by the model data, whereby most data points 
for Omnitrope-treated children fell within the 
defined limits of the prediction model based on 
Genotropin data. Few adverse drug reactions 
(ADRs) occurred. Conclusions: Switching from 
Genotropin to Omnitrope solution has no 
impact on efficacy or safety in children with 
GHD, and the various rhGH preparations are 
well tolerated. 
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INTRODUCTION
Growth hormone deficiency (GHD), which 
occurs when the pituitary gland produces 
insufficient growth hormone (GH) for adequate 
growth and development, can arise from a 
plethora of pathologies, although the cause 
in individual patients often remains obscure.1 
This pathogenic heterogeneity hinders accurate 
epidemiological estimates; in the United 
Kingdom (UK), GHD of unknown origin occurs 
approximately once in every 3800 births.1 
Untreated males and females with GHD 
typically attain final heights of 134-146 cm and 
128-134 cm, respectively,1 and endure a variety 
of concurrent metabolic and psychosocial 
morbidities, underscoring the importance of 
replacement GH therapy.
Recombinant human GH (rhGH, somatropin) 
stimulates production of insulin-like growth 
factor (IGF-1), which increases bone growth, 
muscle strength, and cardiac output, and 
enhances expression of IGF binding proteins 
(IGFBP-3).2 However, growth response to 
GH treatment varies, even in a relatively 
homogeneous group of patients with defined 
inclusion-exclusion criteria, and with the same 
dose of GH used.3 There are various possible 
reasons for this difference in growth response 
between patients but, at least in individual 
patients, it remains obscure. As a result, each 
treated group of children can be arbitrarily 
subdivided into poor, average, and good 
responders dependent upon growth response. 
Nevertheless, the growth response during the 
first 6-12 months of treatment is predictive 
for further growth,4 and treatment with rhGH 
improves final height; normalizes pubertal, 
sexual, and reproductive maturation; attenuates 
metabolic and cardiovascular risk factors; and 
facilitates adult psychosocial development.5
Originally, therapeutic GH was extracted 
from cadaveric pituitary glands. However, by 
1985, rhGH had replaced pituitary sources. 
More recently, rhGH preparations GH 
biosimilars have been developed. The term 
“biosimilar” mainly defines a drug approval 
procedure, and does not suggest that complex 
biopharmaceuticals deriving from the same 
substance are entirely identical.6 Indeed, the 
scientific and legal viability of biosimilars 
remains a topic of constant interest.7 A 
biosimilar can be considered interchangeable 
with a reference product if the data 
demonstrates that it can be expected to produce 
the same clinical result in any given patient, 
and that the risk associated with alternating 
or switching between the two products is not 
greater than that involved in continuing to use 
the reference product.8 In 2006, Omnitrope 
(Sandoz GmbH, Kundl, Austria) was granted 
market authorization under a new “biosimilar” 
regulatory pathway in Europe. This new 
pathway requires an extensive comparability 
exercise throughout the whole development 
process, including a phase 3 clinical study.9
In this study, the comparability of Omnitrope 
and its reference product, Genotropin (Pfizer 
Limited, Sandwich, UK), was demonstrated over 
9 months.10 A subsequent analysis demonstrated 
that Omnitrope’s safety and efficacy was 
maintained during 7 years’ treatment.11 The 
inter-group comparisons confirmed that there 
was no significant difference between the two 
groups, even after switching all patients to 
Omnitrope. However, despite these data, and 
the decades of experience in treating patients 
with rhGH, some commentators have suggested 
caution in switching patients from one type 
of rhGH to another, suggesting an impact on 
efficacy and safety.12
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In an attempt to address this issue, the 
current paper analyzes data from three phase 
3 clinical studies10,11,13,14 to assess the efficacy, 
safety, and immunogenicity of Omnitrope 
in children switching from Genotropin to 
Omnitrope, compared with continuous 
Omnitrope treatment alone. 
METHODS
This paper is based on three studies: the AQ 
study;10,11 the Lyo study;13 and the Spanish 
study.14 Briefly, the AQ study consisted of two 
groups; patients in group A received Omnitrope 
powder in solution for injection (Omnitrope 
lyo) for 15 months, then received Omnitrope 
ready-to-use solution for injection (Omnitrope 
liquid) between months 15-84 (Figure 1).10,11 The 
45 patients in group B received Genotropin for 
9 months, and then switched to Omnitrope 
liquid until the end of the study. The 
comparison between the two groups has already 
been discussed in a previous publication.10
Thus, the current paper assesses outcomes 
of group B only, and compares these results 
with patients continuously treated with 
Omnitrope in the Lyo and Spanish studies. 
The Lyo study assessed continuous treatment 
with Omnitrope lyo for up to 54 months.13
The Spanish study assessed continuous treatment 
with Omnitrope liquid for up to 60 months.14
The current analysis includes 51 patients from 
the Lyo study and 70 from the Spanish study. In 
all studies, the patients were treated with a daily 
injection of 0.03 mg/kg body weight/day rhGH.
The comparative analyses focus on the first 
18 months of GH treatment. Standardized growth 
curves were compared before and after switching 
from Genotropin to Omnitrope (AQ study) and 
with continuous Omnitrope treatment (Lyo and 
Spanish studies) at baseline, 3, 6, 9, 12, 15, and 
18 months. In terms of efficacy, two types of 
analyses were carried out. In a more traditional 
approach, the (standardized) growth curves 
were compared between switched children and 
children continuously treated with the same GH. 
The second analysis is based on a log-function 
model fitted to the growth observed during the 
9 months’ treatment with Genotropin, and then 
used to predict growth for a subsequent 9 months 
as if Genotropin treatment had continued. These 
predictions were compared to the observed 
height after the switch to Omnitrope liquid. 
Concentrations of IGF-I and IGFBP-3 were 
measured as further surrogates of GH efficacy. 
The incidences of anti-GH antibodies during 
the first and second 9 months of treatment as 
well as overall in switched and in nonswitched 
patients were compared to assess immunogenic 
potential. Safety was assessed based on the 
overall incidence of adverse drug reactions 
(ADR), as well as in the first and second 
9-month periods of treatment in switched and 
nonswitched patients. 
Descriptive statistics are provided as means 
± SD or 95% CI.
RESULTS 
Demographics
Table 1 summarizes the demographic and 
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Figure 1. Design of AQ study, Lyo study, and Spanish 
study. Omn=Omnitrope.
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population in the three studies, which are 
broadly similar despite some minor differences 
in the age and gender profiles. In the AQ study, 
one patient was excluded due to noncompliance 
during the first month, and another at month 15,
also for noncompliance.
Efficacy
Comparison of the (Standardized) Growth 
Development Between Switched and 
Nonswitched Patients
The curves for the development of height 
(Figure 2) and height SD score (SDS) (Figure 3, 
Table 2) do not show any apparent differences 
between children who received Genotropin 
followed by Omnitrope liquid and children 
treated continuously with either Omnitrope lyo 
or liquid. The change from baseline in height 
SDS (Figure 4), development of height velocity 
over time (Figure 5), and development of height 
velocity SDS (peak-centered, standardized 
according to Tanner;17 Figure 6, Table 3) over 
time are nearly identical and parallel, with 
differences at baseline carried forward during 
the treatment phase for all three studies. The 
curves for parameters describing height velocity 
show a similar decline after reaching slightly 
different peak responses after the first 3 months 
of treatment. 
AQ study* Lyo study Spanish study
Number of patients, n 45 51 70
Mean age at first visit, years (SD) 7.4 (2.8) 7.6 (2.6) 8.7 (2.4)
Male patients, n (%) 21 (47) 30 (59) 44 (63)
Mean height SDS at first visit (%) –2.99 (0.72) –3.21 (1.00)† –2.98 (0.60)‡
Mean weight at first visit, kg (SD) 20.1 (7.5) 19.9 (6.2) 23.8 (6.7)
Caucasian patients, n (%) 44 (100)§ 51 (100) 69 (99)
Patients with primary insufficiency of GH secretion, n (%) 44 (100)§ 51 (100) 68 (97)
Patients with secondary insufficiency of GH secretion, n (%) 0 (0) 0 (0) 2 (3)
Table 1. Summary of demographic and baseline characteristics of the intent-to-treat population in the AQ, Lyo, and Spanish 
studies.
*Group B of AQ study.
†Ferrández Longas reference.15
‡Prader et al reference.16
§One patient excluded for noncompliance at month 1.
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Figure 2. Development of height over time.
Figure 3. Development of height SD score (SDS) over time. 
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Concentrations of IGF-I and IGFBP-3 rose 
during treatment with rhGH (Table 4) in all 
three studies, and the trend appeared to be 
comparable between studies.
Model-Based Analysis
A log-function model fitted growth data observed 
during 9 months of treatment with Genotropin. 
Based on this model, the height up to month 18 
was predicted and compared to the corresponding 
observed data. Figure 7 shows the prediction 
intervals together with the observed height 
measurements up to month 9 and beyond. Most 
values fall within the predicted boundaries. Patients 
with height measurements outside the predicted 
limits were also outside at baseline. Figure 8 shows 
individual predicted intervals versus observed 
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Figure 5. Development of height velocity (HV) over time.
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Table 2. Comparison of differences in height SD score from baseline between the AQ, Lyo, and Spanish studies.
*Group B of AQ study.
rhGH=recombinant human growth hormone. 
Number of patients varies depending on the available data at each visit.
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Safety
All regimens were well tolerated, with 
few children experiencing ADRs (Table 5). 
For example, in the Spanish study, only 10 of 
the 69 children experienced an ADR at any time 
during the 5-year follow-up. During the first 
9 months, only five patients were affected by 
ADRs, and in the second 9-month period only 
three patients were affected. Only one patient 
was affected in both study periods. 
In general, more ADRs were observed 
during the first than the second 9-month 
period of treatment, whether the patients 
were switched from Genotropin to Omnitrope 
liquid or stayed continuously on the same 
treatment (Table 5).
Immunogenicity
Immunogenicity was uncommon in the 
groups included in this analysis. For instance, 
no relevant increased risk of anti-GH 
antibodies emerged following the switch 
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Figure 6. Development of height velocity (HV) SD score 
(SDS) (Tanner, peak-centered) over time.
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Table 3. Comparison of differences in height velocity SD score from baseline between the AQ, Lyo, and Spanish studies.
*Group B of AQ study. 
rhGH=recombinant human growth hormone. 
Number of patients varies depending on the available data at each visit.
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presence of anti-GH antibodies in more 
than one test during the first 9 months of 
treatment with Omnitrope liquid could 
be detected in only one patient (Table 6).
After the 18-month period, another case of 
possible immunogenicity was detected, but 
this was of very short duration.
Similarly, no patient in the Lyo study 
developed anti-hGH antibodies during the first 18 
months of treatment with Omnitrope Lyo. The 
only child who developed anti-GH antibodies 
showed the first positive results by month 30. 
In the Spanish study, two children showed 
sustained positive antibody results for at least 
Table 4. Comparison of differences in insulin-like growth factor (IGF)-1 and IGF binding proteins (IGFBP)-3 from 
baseline between the AQ, Lyo, and Spanish studies.
*Group B of AQ study. 
†Data unavailable for months 15 and 18. 




























































































































8 Biol Ther (2011) 1(1):005
Figure 7. Prediction intervals versus observed growth data in switched patients. Figure shows height data of 45 switched 














Table 5. Incidence of adverse drug reactions during the first 18 months of treatment in all three studies.
Baseline-9 months 9-18 months Odds ratio
n % n %
AQ study* (n=44) 19 43.2 16 36.4 0.84
Lyo study (n=50) 12 24.0 10 20.0 0.83
Spanish study (n=69) 5 7.2 3 4.3 0.60
*Group B of AQ study. 
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Figure 8. Nine examples of individual prediction intervals versus observed growth data in switched patients. Area between 



























three consecutive visits during the first 9 months 
of treatment. In both cases, the results were 
negative by month 30.
DISCUSSION
The present study confirms what has already been 
established in the phase 3 Omnitrope trial,10,11
in that there is no difference in the efficacy or 
safety of patients switched from Genotropin 
to Omnitrope compared to patients receiving 
Omnitrope throughout the treatment period.
The authors’ analysis has certain limitations. 
Firstly, these results are based on a post-
hoc analysis rather than from a prospective 
comparative trial. However, the current 
10 Biol Ther (2011) 1(1):005
analysis was not intended to demonstrate 
that Omnitrope has an efficacy and safety 
profile similar to that of Genotropin, which 
was already known. The real value of this 
analysis was to address the frequently debated 
fact that patients should not be switched 
between treatments. This analysis showed 
no signal that switching rhGH preparation 
would undermine safety or efficacy, and there 
was no evidence of any difference in clinical 
outcomes with the various rhGH preparations. 
A second limitation is that patients may vary 
in responsiveness to treatment. In the switched 
group of the AQ study, as well as in the Lyo and 
Spanish studies, a small proportion of patients 
were poor responders, while a similar proportion 
were very sensitive and grew faster than the 
other patients.18 Future analyses could examine 
whether sensitivities to rhGH could influence 
responses following a switch between rhGH 
preparations. 
Thirdly, the observational period for this 
analysis was limited to 9 months before and after 
switching therapy, or 18 months’ continuous 
treatment. During this timeframe there were 
very few cases of immunogenicity. However, 
it is known that the most sensitive period 
regarding immunogenicity in GH treatment is 
the first year following treatment initiation,19
and this time period is covered within this 
analysis. Further studies with a longer follow-up 
are needed to confirm the promising profile 
seen in this switch analysis. However, this 
caveat applies to all outcomes with different 
rhGH preparations. Indeed, a consensus group 
concluded that prolonged follow-up in large 
cohorts and accurate estimates of expected 
background population disease rates are needed 
to exclude an increased risk of malignancy, 
diabetes mellitus, or other rare adverse events 
associated with childhood rhGH therapy.3
Finally, despite the potentially devastating 
consequences on height and other outcomes, 
poor adherence is relatively common among 
patients receiving rhGH. Indeed, some studies 
suggest that nonadherence rates are between 
36%-49%.20 In the AQ study, there was no 
examination addressing whether adherence rates 
differed before and after the switch. However, 
the very similar efficacy rates and the absence of 
an a priori reason to suspect pharmacodynamic 
differences between the rhGH preparations 
suggest that adherence rates were similar and 
thus, the groups are comparable.
Receiving market authorisation under 
the new regulatory biosimilar pathway 
requi res  the  implementat ion of  an 
extensive comparability exercise with an 
established, authorized product. Thus, 
in the AQ phase 3 study, Omnitrope 
(AQ group A) demonstrated comparability 
regarding efficacy and safety profile with 
Genotropin (AQ group B – switched group).10,11
This indicates that Genotropin and Omnitrope 
are equally effective, a suggestion confirmed 
by the lack of significant difference in the 
biochemical surrogate markers IGF-I and 
IGFBP-3 (Table 4). Furthermore, the projected 












































Table 6. Incidence of anti-growth hormone (GH) 
antibodies* during the first 18 months of treatment and 
overall.
*Presence of an anti-GH antibody is defined by at least two 
consecutive positive test results.
†Group B of AQ study. 
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cm in boys; an increase of 14 cm over baseline 
projections in both sexes, although the mean 
height velocity suggests there is still potential 
for further growth (data not shown). These 
efficacy results are consistent with growth 
profiles observed for other rhGH products.20 
Also, the efficacy, safety, and immunogenicity 
results in the Lyo and Spanish studies are as 
expected, and show that Omnitrope is an 
effective and well-tolerated treatment that 
increases the likelihood that children with 
GHD will reach a full height potential. In 
all three studies, the patients gained 1.04, 
1.22, and 1.06 height SDS after 18 months 
of treatment for the AQ, Lyo, and Spanish 
studies, respectively. 
For most medications used in the basic 
treatment of patients, switching between 
different preparations within the same 
International Nonproprietary Name (INN) 
is normal daily practice. In most health 
systems, this practice is recommended or 
even mandatory from a health economic 
perspective. Also, during therapy with rhGH 
several patients will be switched because 
of various reasons, including economic 
considerations, eg, due to instructions from 
health authorities. Despite these facts, a 
dogma still exists that patients should not 
be switched during treatment. Of course, 
the situation regarding GH treatment is a 
little more sensitive. In pediatric indications, 
treatment starts at a very young age. The 
children get used to their treatment and 
learn to trust their medication and device. 
As every rhGH is administered with its own 
specific device, a change of rhGH also means 
training the patient in the use of a new 
device. However, this can be easily solved 
by educating patients and switching to an 
easy-to-use device. The current data, which 
would ideally be confirmed in a prospective 
comparative trial, may represent first-line 
knowledge for Public Health Authorities with 
regards to the decision of switching between 
different preparations within the same INN 
being either recommended or even becoming 
mandatory.
By analyzing the potential difference 
in efficacy, safety, and immunogenicity 
in patients switching from Genotropin 
to Omnitrope compared with continuous 
Omnitrope treatment, this paper presents new 
scientific data regarding this topic and shows 
that switching from Genotropin to Omnitrope 
liquid does not show differences in efficacy, 
safety, or immunogenicity and, therefore, 
switching seems to be safe. 
This analysis confirms that there is no 
appreciable difference in height development 
between children who received continuous 
treatment with either Omnitrope liquid or lyo, 
and those who switched from Genotropin to 
Omnitrope liquid. The curve for parameters 
related to height velocity show a similar decline 
after reaching slightly different peak responses 
after the first 3 months of treatment. These 
initial differences are mainly attributable to 
different age and sex profiles in the three 
populations, but the differences are still within 
the same CI. 
In general, ADRs were more frequent during 
the first 9 months of treatment rather than the 
second, irrespective of whether the children 
switched from Genotropin to Omnitrope liquid 
or received continuous treatment with either 
lyo or liquid Omnitrope preparation. The odds 
ratios (OR) of experiencing an ADR in the 
second 9 months compared to the first 9 months 
were comparable in the AQ and Lyo studies. 
The difference between the first and second 
9 months was more marked for the Spanish 
study, although these data require cautious 
interpretation due to the small incidences. 
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In the analyzed studies (switched group, 
Lyo, and Spanish study) immunogenicity was 
uncommon and no relevant increased risk 
of anti-GH antibodies emerged following the 
switch from Genotropin to Omnitrope liquid. 
The switch does not appear to increase the risk 
of immunogenicity. Based on these analyses, 
children can switch safely from one product, 
such as Genotropin, to Omnitrope. 
The ability to switch to a more affordable, 
comparable product without compromising 
outcomes could improve access to rhGH 
as well as potentially releasing resources 
that purchasers could deploy to meet other 
healthcare priorities. In the United States 
alone, approximately 1:3500 children need 
treatment for GHD with GH products,21
and approximately 400,000 children with 
idiopathic short stature,22 according to 
the definition of Rekers-Mombarg et al.,23
qualify for GH treatment. However, rhGH 
can cost $20,000 or more per year for a 
30 kg child and treatment may last at 
least 5 years.24 Although expensive, one 
analysis estimated an incremental cost-
effectiveness ratio of rhGH for idiopathic 
short stature of $52,634 per inch gained 
(2.54 cm), or $99,959 per child, compared 
to no therapy.25 Similarly,  a Swedish 
study estimated an incremental cost per 
quality-adjusted life-year of GH therapy 
of SEK 240,831 for children born small for 
gestational age, and SEK 120,494 for GHD.26
While many healthcare purchasers consider 
such cost-effectiveness ratios as acceptable,20
biosimilars reduce acquisition costs and, as 
the outcomes are the same, improve cost-
effectiveness ratios. In the UK, for example, 
Omnitrope costs between 20% and 30% less 
than other rhGH preparations.2 Therefore, 
biosimilars potentially increase accessibility 
to biopharmaceuticals.18
CONCLUSION
Switching from Genotropin to Omnitrope liquid 
has no negative impact on efficacy, safety, and 
immunogenicity. Growth outcomes and effects 
on IGF-1 and IGFBP-3 continue as expected 
and show no appreciable difference to children 
treated continuously with Omnitrope. The lyo 
and liquid Omnitrope preparations are well 
tolerated, and switching does not adversely 
affect safety. Thus, the Omnitrope preparations 
and Genotropin are comparable. Switching to a 
product which undergoes an extensive clinical 
comparability exercise seems to be safe.
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